CUSIP No.
759757 10 7
|
|
Page 1 of 4
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities
Exchange Act of 1934
(Amendment No. 3 )*
Rennova Health, Inc.
(Name of Issuer)
Common Stock, $.01 par
value
(Title of Class of Securities)
759757 10 7
(CUSIP Number)
Francisco Roca, III
400 South Australian Avenue, 8
th
Floor
West Palm Beach, FL 33401
(561) 855-1626
(Name, Address and Telephone
Number of Person Authorized to Receive Notices and Communications)
September 21, 2016
(Date of Event which Requires
Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box
[_]
.
Note
: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.
See §
240.13d-7
for other parties to whom copies are to be sent.
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP No.
759757 10 7
|
|
Page 2 of 4
|
1.
|
Names of Reporting Persons
Francisco Roca, III
|
2.
|
Check the Appropriate Box if a Member of a Group
(a)
☐
(b)
☐
|
3.
|
SEC Use Only
|
4.
|
Source of Funds (See Instructions)
OO
|
5.
|
Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)
☐
|
6.
|
Citizenship or Place of Organization
United States
|
Number Of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
7.
|
Sole Voting Power
6,477,246
|
|
8.
|
Shared Voting Power
-0-
|
|
9.
|
Sole Dispositive Power
6,477,246
|
|
10.
|
Shared Dispositive Power
-0-
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
6,477,246
|
12.
|
Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
o
|
13.
|
Percent of Class Represented by Amount in Row (11)
11.2%
|
14.
|
Type of Reporting Person
IN
|
|
|
|
|
|
CUSIP No.
759757 10 7
|
|
Page 3 of 4
|
Item 1. Security and Issuer
This Amendment
No. 3 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, as previously amended by Amendments No. 1
and No. 2 to Schedule 13D, with respect to the Common Stock, $0.01 par value per share (the "Shares"), of Rennova Health,
Inc., a Delaware corporation (the "Issuer"), filed by Francisco Roca, III. Except as expressly amended below, the Schedule
13D, dated November 2, 2015, as previously amended, remains in effect.
Item 3. Source and Amount
of Funds or Other Consideration
Item 3
is hereby amended to include the following:
This Amendment
No. 3 to Schedule 13D is being filed to report the issuance to Mr. Roca on September 21, 2016 of 1,146,789 Shares upon conversion
of 1,000 shares of the Issuer's Series B Convertible Preferred Stock owned of record by Mr. Roca.
Item 5. Interest
in Securities of the Issuer
Item 5 is
hereby amended to include the following:
As of September
21, 2016, Mr. Roca may be deemed to beneficially own 6,477,246 Shares (or approximately 11.2% of the total number of Shares deemed
outstanding), which consists of (i) 3,739,847 Shares, (ii) 2,000,000 stock options owned of record by Mr. Roca to purchase a like
number of Shares, and (iii) 737,399 warrants owned of record by Mr. Roca, to purchase a like number of Shares; all as to which
Mr. Roca has sole dispositive and voting power.
CUSIP No.
759757 10 7
|
|
Page 4 of 4
|
SIGNATURES
After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
November 30, 2016
|
/s/ Francisco Roca, III
Francisco Roca, III
|
|
|
|
|